Role of long-term cyclosporine eye drop use in vernal keratoconjunctivitis in preventing corneal ectasia

Efficacy of long-term inflammation control with 0.05% Cyclosporine eye drops in preventing development of Keratoconus in Vernal Keratoconjunctivitis: A Randomized Controlled Study - CIPK

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017478

Enrollment

200

Registered

2019-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H101- Acute atopic conjunctivitis

Interventions

Intervention1: Cyclosporine 0.05%: Cyclosporine 0.05% eye drops will be provided one drop two times a day for 6 months Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases with severe VKC 2. Appropriate consent

Exclusion criteria

Exclusion criteria: • Mild-moderate cases of VKC • VKC with complications • Ocular inflammatory disorders other than VKC • Known case of steroid responder • Any previous surgery for VKC related complications • Cases on oral anti-inflammatory or oral anti-allergy therapy • Cases on topical anti-inflammatory drugs within 4 week of enrollment • History of sensitivity to any constituents of the eye drops

Design outcomes

Primary

Measure	Time frame
Change in KeratometryTimepoint: at 6, 12 months after completion of therapy	—

Secondary

Measure	Time frame
o Change in Corneal thickness (Central, Thinnest location on Pentacam) o Recurrence of VKC Timepoint: at 6, 12 months after completion of therapy	—

Countries

India

Contacts

Public ContactPrafulla Kumar Maharana

AIIMS, New Delhi

drpraful13@gmail.com7978735802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026